Charles River Laboratories International (CRL) Asset Utilization Ratio (2010 - 2026)
Charles River Laboratories International (CRL) posted Asset Utilization Ratio of 0.52 for Q2 2026, down 3.28% on a QoQ basis from 0.54 in Q1 2026, and down 1.51% year-over-year from 0.53 in Q2 2025.
Analysis
Charles River Laboratories International (CRL) Asset Utilization Ratio (2010 - 2026) Analysis & Trends
Charles River Laboratories International has reported Asset Utilization Ratio for 17 years, with the latest figure at 0.52 in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio fell 1.51% year-over-year to 0.52 in Q2 2026; TTM through Jun 2026 was 0.52, a 1.51% decrease from a year earlier, with the FY2025 full-year figure at 0.55, up 6.31% from the prior year.
- Asset Utilization Ratio was 0.52 for Q2 2026 at Charles River Laboratories International, down from 0.54 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.55 in Q3 2023, with the low at 0.5 in Q1 2024.
- Average Asset Utilization Ratio over 5 years is 0.53, with a median of 0.53 recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio climbed 8.1% in 2023, then decreased 7.13% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.53 in 2022, then decreased by 1.51% to 0.52 in 2023, then decreased by 0.22% to 0.52 in 2024, then advanced by 5.12% to 0.55 in 2025, then retreated by 4.41% to 0.52 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.52 (Q2 2026), 0.54 (Q1 2026), and 0.55 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 0.57 |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 1.33 |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 0.50 |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 0.52 |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 0.99 |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 0.11 |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 2.01 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 0.84 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | 0.02 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 0.52 |
| Mar 28, 2026 | 0.54 |
| Dec 27, 2025 | 0.55 |
| Sep 27, 2025 | 0.53 |
| Jun 28, 2025 | 0.53 |
| Mar 29, 2025 | 0.53 |
| Dec 28, 2024 | 0.52 |
| Sep 28, 2024 | 0.51 |
| Jun 29, 2024 | 0.51 |
| Mar 30, 2024 | 0.50 |
| Dec 30, 2023 | 0.52 |
| Sep 30, 2023 | 0.55 |
| Jul 1, 2023 | 0.54 |
| Apr 1, 2023 | 0.53 |
| Dec 31, 2022 | 0.53 |
| Sep 24, 2022 | 0.51 |
| Jun 25, 2022 | 0.51 |
| Mar 26, 2022 | 0.51 |
| Dec 25, 2021 | 0.50 |
| Sep 25, 2021 | 0.50 |